Cumulus Neuroscience

Cumulus operates at the intersection of neuroscience, digital health, and clinical-trial technology. Its NeuLogiq platform combines digital assessments with measures such as EEG, cognition, mood, speech, and sleep, supporting repeated monitoring both in clinics and at home. That multimodal, longitudinal approach distinguishes its stated offering from tools focused on a single assessment or a single setting, while its trial-design, deployment, and analysis services address operational needs beyond data collection. The company has announced collaborations with pharmaceutical developer Shionogi and neurotechnology company Muse by Interaxon, as well as work with Delix Therapeutics, demonstrating use cases across CNS drug studies. The available profile does not identify verified competing companies; similarity entries resolve to Cumulus itself, so naming them as competitors would be misleading. Muse by Interaxon is a collaborator, not established here as a competitor. Cumulus’s competitive position therefore appears to depend on demonstrating that its combined measures are reliable, usable across study sites and homes, and valuable for trial decisions. Its 2026 validation announcements and conference presentations add evidence, but do not by themselves establish comparative market share or clinical adoption.

Cumulus has developed from a Belfast-founded company established in 2015 into a clinical technology business with a platform spanning digital assessments and neurophysiological monitoring. Its funding history shows several stages of support: a £6 million venture round in 2021, two Innovate UK grants in 2024, and a £3.5 million venture round led by Whiterock Finance on Jul 8, 2025. Total funding is $15,898,140 across four rounds. The more visible recent inflection is commercial and product expansion rather than a disclosed acceleration in headcount: the company announced its Japan entry with Shionogi in February 2026, a Delix Therapeutics collaboration in May, and integration of Muse’s at-home sleep EEG in July. It also reported validation work on dry-EEG neuroplasticity measurement in January 2026 and continued clinical-evidence announcements through September. The employee band remains 11–50, and hiring signals cite activity in Japan, the United States, and Australia without specifying role counts.